Loading stock data…
CRISPR Therapeutics AG (CRSP)
N/A
Market Closed
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
Historical Price
No chart data available for CRSP
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.00M | $0 | $0 | $0 | $0 |
| Gross Profit | -$44.95M↑ | -$53.70M↑ | -$57.12M↓ | -$45.15M↑ | -$57.51M |
| Operating Income | -$130.25M↑ | -$154.76M↓ | -$132.06M↑ | -$229.32M↓ | -$148.42M |
| Net Income | -$122.93M↑ | -$130.61M↓ | -$106.44M↑ | -$208.55M↓ | -$136.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The compan...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-31.33%
Volume
Today's trading volume
-
Recent News
Tesla’s 10% Weight in ARKK Sets Up a Make-or-Break Year for the Innovation ETF
The ARK Innovation ETF (NYSEARCA:ARKK) has barely moved this year, gaining about 2% year to date through late June and sitting at roughly $78 per share. That stasis hides a violent tug of war inside the portfolio: AMD has more than doubled, up 144% YTD, while Coinbase has shed 34% and Tesla (NASDAQ:TSLA), ARKK’s largest ... Tesla’s 10% Weight in ARKK Sets Up a Make-or-Break Year for the Innovation ETF
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting financials and risk profiles.
CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors
CRISPR Therapeutics AG (CRSP) closed at $54.92 in the latest trading session, marking a +1.74% move from the prior day.
3 Companies Redefining Healthcare Innovation
The Healthcare Technology and Innovation index (HTEC) was launched back in 2019 with a specific purpose in mind: to allow investors to participate in the evolution of healthcare needed to address critical societal challenges. Issues such as an aging population, rising medical costs, and a shortage of skilled healthcare workers drove the creation of the [...]
Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year
The opportunity is enormous, but uncertainty remains.